Company intelligence / Profile preview

Abacus Diagnostica

Turku, Southwest Finland, Finland

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Abacus Diagnostica developed and commercialized the GenomEra CDX rapid PCR platform for molecular diagnostics of infectious diseases. The CE-marked IVD platform provided results in approximately one hour without DNA/RNA extraction. The company successfully commercialized multiple diagnostic tests including COVID-19, influenza, RSV, norovirus, C. difficile, MRSA, and Group B Streptococcus diagnostics.

Therapeutic areas: Infectious Diseases
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Abacus Diagnostica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abacus Diagnostica.

Explore the full profile